5x5g

Publication Abstract from PubMed

The development of effective inhibitors that block extended-spectrum beta-lactamases (ESBLs) and restore the action of beta-lactams represents an effective strategy against ESBL-producing Enterobacteriaceae We evaluated the inhibitory effects of the diazabicyclooctanes avibactam and OP0595 against TLA-3, an ESBL that we identified previously. Avibactam and OP0595 inhibited TLA-3 with apparent inhibitor constants (Kiapp) of 1.71 +/- 0.10 and 1.49 +/- 0.05 muM, respectively, and could restore susceptibility to cephalosporins in the TLA-3-producing Escherichia coli strain. The value of the second-order acylation rate constant (k2/K, where k2 is the acylation rate constant and K is the equilibrium constant) of avibactam [(3.25 +/- 0.03) x 10(3) M(-1) . s(-1)] was closer to that of class C and D beta-lactamases (k2/K, <10(4) M(-1) . s(-1)) than that of class A beta-lactamases (k2/K, >10(4) M(-1) . s(-1)). In addition, we determined the structure of TLA-3 and that of TLA-3 complexed with avibactam or OP0595 at resolutions of 1.6, 1.6, and 2.0 A, respectively. TLA-3 contains an inverted Omega loop and an extended loop between the beta5 and beta6 strands (insertion after Ser237), which appear only in PER-type class A beta-lactamases. These structures might favor the accommodation of cephalosporins harboring bulky R1 side chains. TLA-3 presented a high catalytic efficiency (kcat/Km ) against cephalosporins, including cephalothin, cefuroxime, and cefotaxime. Avibactam and OP0595 bound covalently to TLA-3 via the Ser70 residue and made contacts with residues Ser130, Thr235, and Ser237, which are conserved in ESBLs. Additionally, the sulfate group of the inhibitors formed polar contacts with amino acid residues in a positively charged pocket of TLA-3. Our findings provide a structural template for designing improved diazabicyclooctane-based inhibitors that are effective against ESBL-producing Enterobacteriaceae.

Structural Insights into the TLA-3 Extended-Spectrum beta-Lactamase and Its Inhibition by Avibactam and OP0595.,Jin W, Wachino JI, Yamaguchi Y, Kimura K, Kumar A, Yamada M, Morinaka A, Sakamaki Y, Yonezawa M, Kurosaki H, Arakawa Y Antimicrob Agents Chemother. 2017 Sep 22;61(10). pii: AAC.00501-17. doi:, 10.1128/AAC.00501-17. Print 2017 Oct. PMID:28739781^[1]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.